Gilead acquires CAR-T specialist Arcellx for $7.8bn

Gilead has agreed to acquire Arcellx in a deal worth $7.8bn, as the drugmaker looks to add a CAR T-cell therapy for blood cancer treatment on the cusp of approval to its portfolio. As per the agreement, Gilead will pay $115 per share, as well as a one contingent value right of $5 each. The deal is expected to close in Q2 2026. The acquisition marks the culmination of a period of collaboration between the two companies. In 2022, Gilead, via its subsidiary Kite, entered a research and development partners ...